🔬 Next-Generation Hormonal Therapy (Abiraterone/Enzalutamide) Simulator

Baseline CRPC — Androgen Deprivation Isn't Enough

Testes are silenced, but the tumor keeps growing on leftover androgen.

• ~95% cut: Testicular testosterone (via ADT / orchiectomy)
• DHEA, ASD: Adrenal androgen source (converted intratumorally)
• Active: Intratumoral synthesis (tumor makes its own fuel)
• ~18–24 mo: CRPC onset (median after ADT start)

Why castration alone fails

Adrenal glands and tumor cells keep producing androgen precursors.

Residual androgen signaling

Small amounts of androgen are enough to keep AR active.

Clinical implication

Need drugs that hit the residual pathway directly.

Placeholder callout — residual androgen keeps CRPC alive.

Abiraterone — Shutting Down CYP17 at the Source

Blocks the enzyme that makes androgen, before it ever forms.

• CYP17A1: Target enzyme (17α-hydroxylase / C17,20-lyase)
• Adrenal + tumor: Synthesis site blocked (both sources hit)
• + prednisone: Co-administered (offsets mineralocorticoid excess)
• 1000 mg/day: Typical dose (oral, once daily)

CYP17 enzyme role

Converts cholesterol precursors into androgen building blocks.

Upstream shutdown

No enzyme activity means no new androgen molecules form.

Downstream effect

Receptor has nothing left to bind.

Placeholder callout — supply cut off before synthesis.

Enzalutamide — Blocking the Androgen Receptor Directly

Androgen still forms, but can no longer signal through AR.

• Androgen receptor: Target (competitive antagonist)
• Blocked: Nuclear translocation (AR can't enter nucleus)
• Blocked: DNA binding (no transcriptional activity)
• 160 mg/day: Typical dose (oral, once daily)

AR antagonism

Occupies the receptor's binding pocket, blocking androgen.

Downstream consequences

No nuclear translocation, no gene transcription.

Contrast with abiraterone

Production continues; only signaling is stopped.

Placeholder callout — receptor blocked regardless of supply.

Supply vs Receptor — Two Ways to Stop the Same Signal

Same goal, two blockade points along one pathway.

• CYP17 (supply): Abiraterone target (upstream enzyme)
• AR (receptor): Enzalutamide target (downstream signaling)
• Low AR activity: Shared endpoint (via different routes)
• Partial: Cross-resistance (some tumors escape either)

Pathway position

One acts upstream, the other acts at the receptor.

Complementary logic

Blocking both points narrows the tumor's escape routes.

Sequencing considerations

Order and combination affect resistance patterns.

Placeholder callout — mechanisms complement, not duplicate.

Convergent Suppression of Residual Androgen Signaling

Both drugs land at the same place: minimal AR activity.

• Low: Net AR signaling (via either mechanism)
• Common: Sequential use (switch on progression)
• Ongoing: Combination trials (with chemo, PARP, etc.)
• Established: Survival benefit (vs. ADT alone in CRPC)

Convergent efficacy

Different blockade points, same suppressed-signaling outcome.

Sequencing and combination

Often used one after another or alongside other agents.

Clinical takeaway

Complementary mechanisms broaden treatment options.

Placeholder callout — two paths, one durable suppression.